Skip to main content

MoneyWorks4Me

Zydus Lifesciences informs about press release

30 Aug 2022 Evaluate
Zydus Lifesciences has informed about Press Release dated August 30, 2022 titled 'Zydus announces Phase IV DREAM-CKD trial to generate Real World Evidence of Desidustat in patients with chronic kidney disease induced anemia'.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1915.10
Dr. Reddys Labs. 1369.00
Cipla 1410.95
Lupin 1995.00
Zydus Lifesciences 1200.00
View more..